James Crowe

March 2, 2017

Clinical investigation society lauds impact of Crowe’s research

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017 recipient of the Stanley J. Korsmeyer Award given by the American Society for Clinical Investigation (ASCI), one of the nation’s oldest and most respected honor societies for physician-scientists.

By Bill Snyder
February 23, 2017

Crowe’s pediatric immune response research lauded

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017-2018 recipient of the Samuel Rosenthal Prize for Excellence in Academic Pediatrics.

By Bill Snyder
February 9, 2017

Team isolates new antibodies that may aid RSV vaccine design

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.

By Bill Snyder
January 19, 2017

Digestive Disease Research Center lands major grant

The Vanderbilt Digestive Disease Research Center (VDDRC) celebrates its 15th anniversary this year with a third consecutive five-year renewal of its federal research grant.

By Jill Clendening
December 15, 2016

2016 a year of milestones, accomplishments for VUMC

The following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2016.

By Doug Campbell
November 7, 2016

Early study finds antibody that ‘neutralizes’ Zika virus

Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.

By Bill Snyder
October 20, 2016

Preparing for a return of pox

To prepare for the potential of a smallpox return, Vanderbilt researchers are isolating and studying naturally occurring antibodies from the blood of previously infected or immunized people.
By Bill Snyder
October 20, 2016

Research sheds light on how RSV wards off potential vaccines

Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it.
By Bill Snyder
September 8, 2016

Investigators create ‘Trojan Horse’ to fight Ebola

A multi-center research team including scientists from the Vanderbilt Vaccine Center has come up with a clever “Trojan Horse” strategy for thwarting the highly lethal Ebola virus.
By Bill Snyder
August 11, 2016

Research team takes aim at Ebola virus ‘decoy protein’

Using an antibody generated at Vanderbilt University Medical Center that neutralizes the Ebola virus, researchers at the Scripps Research Institute in La Jolla, California, have determined the structure of a “decoy” protein that may enable the virus to evade detection by the immune system.
By Bill Snyder
July 14, 2016

Influx of major NIH grants fuels growth of research enterprise

During the past two weeks, researchers at Vanderbilt University and Vanderbilt University Medical Center (VUMC) have brought in a number of new research grants from the National Institutes of Health (NIH) that together achieve $137 million in new funding. The funding is a trans-institutional accomplishment of the Schools of Engineering and Medicine and the College of Arts and Science.
By Bill Snyder
June 21, 2016

Vanderbilt and Human Vaccines Project launch initial studies to decode the human immune system

Researchers at Vanderbilt University Medical Center this month began recruiting volunteers to participate in a clinical trial aimed at decoding the human “immunome,” the genetic underpinnings of the immune system.
By Bill Snyder
April 7, 2016

Potent HIV antibodies suggest new vaccine development approach

It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks.
By Bill Snyder
1 … 7 8 9 10 11 … 14